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CASE PRESENTATION
A 49-year-old man was referred for evaluation of rising
plasma creatinine. The patient had undergone a partial
gastrectomy 4 years previously, for resection of a
gastrointestinal stromal tumor. He was diagnosed with
recurrent disease, including hepatic involvement 6
months before presentation at the renal clinic, for which
he was initially treated with imatinib mesylate (Gleevec,
Novartis Pharmaceuticals, East Hanover, NJ, USA). Two
months later, his regimen was changed to ifosfamide
(2500 mg/m2 on days 1–3), doxorubicin (20 mg/m2 on days
1–3), and mesna (600 mg/m2 on days 1–3) after the tumor
was reclassified as an inflammatory myofibroblastic
sarcoma. At this time, chemistries were notable for
creatinine 0.9 mg/dl, calcium 10.4 mg/dl, and albumin of
3.2 g/dl. Urine dipstick was notable for trace albuminuria.
Over the next 6 weeks, he received three cycles of
ifosfamideþdoxorubicinþmesna. He also received a
single 90 mg dose of pamidronate for hypercalcemia
(presumed to be caused by his underlying malignancy).
His first course of chemotherapy was complicated by
urinary retention, which resolved spontaneously, and by
neutropenic fever (for which he received a single dose of
gentamicin, 110 mg). In addition, he had mild
hypomagnesemia and hypokalemia. One week after
completing the third course of ifosfamideþdoxorubicin
þmesna, the creatinine increased from 1.0 to 1.5 mg/dl,
the K was 2.5 mmol/l and a urine dipstick revealed trace
proteinuria and hematuria. Oral potassium was prescribed
and the chemotherapy regimen was switched to
gemcitabine and docetaxel (1000 and 40 mg/m2 on days 1
and 8 of 21-day cycle, respectively) because of a concern
regarding ifosfamide-induced encephalopathy. The first
cycle of gemcitabine and docetaxel was complicated by
thrombocytopenia requiring dose reductions by 25%. The
creatinine increased to 2.0 mg/dl after the first cycle and
to 2.4 mg/dl after the second cycle (Figure 1), and the
patient was then referred to the renal clinic.
The patient’s medical history included attention deficit
disorder for which he took methylphenidate. Other
medications were loratidine and darbepoetin alpha; there
were no non-steroidal anti-inflammatory drugs or herbal
preparations. He reported allergies to ciprofloxacin,
penicillin, tetracycline, and minocycline. He had smoked up
to one pack of cigarettes a day for 10 years, quitting 20 years
ago. There was no family history of renal disease or cancer.
Examination showed a white male with pulse
100/min and blood pressure 158/88. The jugular veins
were not distended. The lungs were clear to auscultation;
his heart had a regular rhythm with normal heart
sounds and no murmurs or gallops. The abdomen was
notable for a firm, non-tender mass in the right upper
quadrant. There was trace ankle edema. No skin rashes
were noted.
Laboratory studies revealed: white blood count
3.5 109/l, hemoglobin 9.2 g/dl, platelets 40 109/l,
sodium 141 mmol/l (normal range, 136–142), potassium
3.6 mmol/l (3.5–5.0), chloride 109 mmol/dl (98–108),
bicarbonate 25 mmol/dl (23–32), blood urea nitrogen
22 mg/dl (9–25), creatinine 2.4 mg/dl (0.7–1.3), glucose
107 mg/dl (54–118), calcium 11.0 mg/dl (8.8–10.5),
phosphate 2.3 mg/dl (2.4–5), albumin 3.5 g/dl (3.7–5.4),
and immunoreactive parathyroid hormone 11 pg/ml
(11–80). Urine dipstick revealed pH 5.5, specific
gravity 1.015, no glucose or ketones, 1þ blood,
2þ protein, no nitrites or leukocyte esterase. The
urine sediment showed 15–20 dark granular casts and 2–5
red blood cells per high power field. The spot urine protein/
creatinine ratio was 1.6. Lactate dehydrogenase and
haptoglobin were normal. Parathyroid hormone related
peptide was undetectable; 25-OH and 1,25-OH vitamin D
levels were 25 ng/ml (normal range, 20–57) and 57 pg/ml
(15–75), respectively. A peripheral blood smear did not
reveal any schistocytes. A recent computed tomography
scan of the abdomen (for tumor restaging) demonstrated
normal sized kidneys without hydronephrosis.
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Labetalol 100 mg po b.i.d. and furosemide 20 mg po
q.d. were prescribed for the hypertension. One week later,
the creatinine had increased to 3.0 mg/dl. A major concern
was whether gemcitabine was contributing to the kidney
injury and a renal biopsy was performed.
RENAL BIOPSY FINDINGS
Two cores containing both cortex and medulla were obtained.
On light microscopy, there was mild enlargement of the
glomeruli (nine in total), but otherwise no glomerular
abnormalities. The tubules showed widespread degenerative
changes, characterized by flattening of the epithelial cells,
focal vacuolization of the cytoplasm, isolated calcifications
and several intraluminal sloughed epithelial cells (Figure 2a).
The tubular epithelial cells had evidence of mitotic activity;
individual cell necrosis was present in a few tubules. About 20%
of the tubulointerstitium was atrophic. The degree of vascular
sclerosis was moderate in the small-sized arteries and arterioles.
Immunofluorescence microscopy showed no significant
immune deposits in the three glomeruli present in the sections.
Electron microscopy showed that the architecture of the
glomerular tuft was well preserved, without remodeling of
peripheral capillaries or signs of endothelial injury. The
glomerular visceral epithelial cells were also preserved and no
electron-dense deposits were present along the peripheral
capillary walls or mesangium. Tubules revealed prominent
degenerative changes with loss of brush border in the
proximal segments, and swelling of mitochondria and
endoplasmic reticulum (Figure 2b). The biopsy was inter-
preted as nonspecific, severe acute tubular injury.
CLINICAL FOLLOW-UP
The most likely cause of the patient’s renal failure was felt to
be ifosfamide nephrotoxicity. The gemcitabine and docetaxel
regimen was resumed, given the previous response to this
regimen and the histopathological absence of any renal
thrombotic microangiopathy (TMA). The blood pressure
remained well controlled and there was no new laboratory
evidence of TMA while on further gemcitabine therapy. The
patient received a second and lower dose of pamidronate
(45 mg as a slow infusion) for hypercalcemia. Despite no
further ifosfamide, the creatinine increased to 4.9 mg/dl over
the next few months (Figure 1). The hypophosphatemia and
hypokalemia resolved in the setting of the falling glomerular
filtration rate. The patient developed intermittent glycosuria
with ongoing proteinuria and hematuria; granular casts
persisted in the urine sediment.
He ultimately underwent debulking surgery requiring
gastrectomy, cholecystectomy, and partial hepatectomy with
a complicated postoperative course, included worsening renal
failure requiring the initiation of renal replacement therapy.
DISCUSSION
A broad differential diagnosis must be entertained when
evaluating renal failure in the cancer patient. In addition to
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Figure 1 | Time course (in 2005) of the plasma creatinine in
reference to exposure to various potential nephrotoxins.
a b
Figure 2 | Renal biopsy. (a) Cortex with tubules showing irregularities along the luminal epithelial border, flattening and denudation of
epithelial cells (arrows), loss of brush border of the proximal tubules (asterisk), and intraluminal cell debris (periodic acid-Schiff stain, original
magnification  400). (b) Electron micrograph of a proximal tubule with loss of brush border (arrow), swollen mitochondria, vacuolization of
the cytoplasm (asterisk), and intraluminal sloughed epithelial cells (arrowhead) (uranyl acetate-lead citrate, original magnification  2950).
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being susceptible to pre- and post-renal insults, this
population is at risk for various intrinsic renal pathologies
associated with malignancies, including infiltration by tumor,
tumor lysis syndrome, and paraneoplastic glomerular disease
(Table 1; reviewed by Humphreys et al.,1 Lameire et al.2).
Furthermore, numerous chemotherapies used to treat
malignancies are potentially nephrotoxic (reviewed by
Kintzel3). The patient discussed here was exposed to several
potential renal insults including ifosfamide, gemcitabine,
hypercalcemia, and pamidronate.
Ifosfamide is metabolized to an active alkylating agent,
and is used in the treatment of a wide range of tumors.
Mesna, introduced in the 1980 s, significantly reduced the
incidence and severity of hemorrhagic cystitis caused by
ifosfamide’s reactive metabolites. It is excreted into the urine
by renal tubular cells, where it can form stable thioesters with
toxic, reactive ifosfamide metabolites, including acrolein and
chloroacetaldehyde.4 Unfortunately, mesna does not prevent
ifosfamide’s significant nephrotoxicity.5,6 The exact mechan-
ism of ifosfamide nephrotoxicity remains unclear, but there is
evidence that chloroacetaldehyde acts as a direct tubular
toxin.7 Although ifosfamide can affect any portion of the
nephron, proximal tubule defects are the most common.
Glycosuria, hypophosphatemia, and hypokalemia are thus
relatively common complications; in one study, subclinical
glycosuria was found in 88% of ifosfamide-treated children,8
whereas high-dose ifosfamide was associated with subclinical
serum electrolyte or urinalysis abnormalities in 92% of adult
patients.9 Complete Fanconi syndrome (not documented in
our case) has been reported, as has the development of
nephrogenic diabetes insipidus due to distal tubule dysfunc-
tion.10,11 Persistence of tubular defects for years after cessation
of chemotherapy is common in children and adults.9,12 The
incidence of acute renal failure (usually defined as a creatinine
greater than 2 mg/dl) in adults treated with various doses of
ifosfamide has been reported at 4–17%.9,13–15
Our patient developed several features consistent with
ifosfamide nephrotoxicity: hypokalemia, hypophosphatemia,
glycosuria, dark granular casts in the urine sediment, and
severe tubular damage on light and electron microscopy.
Interestingly, although there was evidence of ifosfamide-
induced tubular damage after the first cycle of this drug,
plasma creatinine did not increase until several cycles had
been administered. Early studies reported either largely non-
progressive chronic renal insufficiency because of ifosfa-
mide15 or a return to baseline creatinine in the majority
(75%) of patients with ifosfamide-induced acute renal
failure (defined as Cr42 mg/dl).13 However, a delayed-onset
of creatinine elevation has since been described, as has
progressive renal failure occurring after discontinuation of
ifosfamide.16–18 Delayed increases in serum creatinine were
reported in 10% of adult patients in one trial.9 Strikingly, of
six children who had a significant decline in glomerular
filtration rate 2 years after treatment with ifosfamide, five had
still had normal renal function at the time they discontinued
the drug.19 Nonetheless, descriptions of progressive severe
nephrotoxicity ultimately leading to end-stage renal disease
are largely limited to case reports.
An important clinical question is whether to halt
ifosfamide treatment in patients with subclinical evidence
of tubular dysfunction such as glycosuria, hypophosphate-
mia, or hypokalemia. Although most will not develop renal
failure, for those who do, there are no treatment options
beyond supportive care; furthermore, renal failure may
progress even after the withdrawal of the drug. Therefore,
the identification of risk factors and predictive algorithms for
the development of chronic ifosfamide nephrotoxicity would
be helpful. Few risk factors are currently well established.7
A correlation between total ifosfamide dose and the degree of
renal dysfunction has been reported in children.8 However,
no clearly safe cumulative dose has been established in
children, and little data are available in adults. Previous or
concurrent exposure to cisplatin (another tubular toxin),
reduced renal mass due to unilateral nephrectomy, or pre-
existing renal disease may increase the risk of ifosfamide
nephrotoxicity.7 Interindividual variation in the metabolism
of ifosfamide to its toxic metabolites has also been postulated
to explain its variable nephrotoxicity. In our patient,
treatment with ifosfamide was discontinued because of a
concern regarding ifosfamide-induced encephalopathy.
Although this adverse effect has also been postulated to be
Table 1 | Causes of renal failure in patients with cancer
(the list is not intended to be exhaustive)
Prerenal
Hypovolemia (vomiting, diarrhea, poor fluid intake, hypercalcemia)
Hepatorenal syndrome (veno-occlusive disease after hemopoietic cell
transplantation)
Intrarenal
Glomerular
Membranous nephropathy (associated with malignancy or
hematopoietic cell transplant)
Membranoproliferative glomerulonephritis including
cryoglobulinemic glomerulonephritis (lymphoproliferative
diseases, rarely solid tumors)
Minimal change disease (lymphomas, rarely solid tumors and
hematopoietic cell transplant)
Amyloid, light-chain deposition disease
Immunotactoid glomerulopathy (lymphomas, leukemias)
Pamidronate-induced collapsing glomerulopathy
Tubulointerstitial
Cast nephropathy (myeloma)
Direct tubular damage (ifosfamide, cisplatin, bisphosphonates)
Tumor lysis syndrome
Light-chain deposition disease
Invasion of renal parenchyma by cancer cells, for example, lymphoma
Drug-induced interstitial nephritis
Vascular
Renal thrombotic microangiopathy (certain cancers, hematopoietic
cell transplantation, gemcitabine, mitomycin)
Postrenal
Retroperitoneal fibrosis
Gynecological malignancies
Intratubular obstruction (methotrexate)
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mediated by the chloroacetaldehyde metabolite, the associa-
tion between development of ifosfamide-induced nephro-
pathy and encephalopathy is weak.
Gemcitabine – a nucleoside analog – is now a commonly
used chemotherapy agent. Severe renal TMA related to
this drug has been reported by us and others.20,21 The
patient’s decline in glomerular filtration rate clearly
preceded his exposure to gemcitabine. However, owing to
the rise in creatinine after switching to a gemcitabine-based
regimen, the development of some stigmata of renal TMA
(new onset hypertension, rising creatinine, hematuria,
thrombocytopenia) and the potentially severe sequelae of
gemcitabine-associated TMA,21 a renal biopsy was performed,
mainly to exclude this possibility. The absence of glomerular
endothelial damage or microvascular thrombosis did exclude
this diagnosis, allowing ‘safe’ continued administration of
gemcitabine. The nephrotoxicity of bisphosphonates –especially
when used at high doses – is increasingly recognized.
High-dose pamidronate has been associated with acute tubular
damage and collapsing glomerulopathy;22 zoledronate has
been associated with acute tubular damage.23 It is possible that
the initial 90 mg dose of pamidronate contributed to the tubular
damage seen here (i.e., was a ‘second hit’), although typically,
higher doses are associated with nephrotoxicity. The
lack of severe proteinuria and the ultrastructural findings
excluded a collapsing glomerulopathy. Certainly in cases
such as ours, where continued administration of bispho-
sphonates is deemed necessary, it seems prudent to reduce the
dose, to infuse more slowly, and to give concomitant normal
saline.
In summary, we describe a case of severe renal failure and
electrolyte wasting because of tubular damage, with the
main etiology being ifosfamide. As in many cases of cancer-
associated kidney disease, multiple potential causes of
kidney damage often coexist. Here, kidney biopsy was helpful
in clarifying the diagnosis and allowing continued
optimal chemotherapy. Our case also illustrates how renal
failure may develop many weeks to months after completing
ifosfamide therapy and that ifosfamide-treated patients
should be closely followed for the development of tubular
dysfunction, although when to discontinue treatment
remains unclear.
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